Market for Impact

Summary

What do they do? Exact recipient EIN27-1103057 redistributes surplus medicines and includes own pharmacy/returns entities. Santa Clara County's independent public Better Health Pharmacy is a verified Bay partner. More

Why this approach interests us

Low-cost logistics can move otherwise unused medicines into sustained treatment, including verified BP and statin classes.

Our main reservations

Stock continuity, fill duration, high-risk mix, residual benefit and marginal public/private alternatives are not measured. Most modeled central health comes from explicit residual-class priors.

What do you get for your dollar?

Central donor cost per10 QALYs: $130,983 US, $4,366,108 Bay, unpriced SF. Gross associated US resources $1,077,665 per10Q. Favorable joint donor assumptions pass nationally and narrowly in Bay; adverse health is negative. Inspect formulas, inputs and sources.

whole gift: $100,000 — 70% modeled delivery allocation; entire gift retained in every regional numerator.
central net health: 7.634564 QALYs — US 7.634564 / Bay 0.229037 / SF0. Residual morbidity6.012826 gross QALYs is an explicit prior.
associated resources: $822,750 gross / $438,032 conditional net — Outside pharmacy and clinical resources included. Donated-drug retail value excluded; net medical savings are uncertain.

1. What do they do?

Exact recipient EIN27-1103057 redistributes surplus medicines and includes own pharmacy/returns entities. Santa Clara County's independent public Better Health Pharmacy is a verified Bay partner.

Budget actual medication-months

Shipped prescriptions become dispensed months; concurrent-drug and funded-duration divisors produce distinct complete-course equivalents.

Separate existing care from new treatment

Financing replacement and sustained-treatment contrast reduce public/insurance/other-donor baseline overlap.

Value finite, disjoint health

Separate BP first-stroke, statin mixed first-event, and residual on-treatment morbidity cohorts; no additive drugs or repeat-event lives.

Scope of this review. Current formulary is evidence of classes, not stock, patient indication or quantity. Trial efficacy is not SIRUM's measured marginal effect.

2. Monitoring and information sharing

Older patients with severe isolated systolic hypertension

Randomized placebo-controlled SHEP trial. Five-year stroke incidence8.2% control versus5.2% treatment; relative rate0.64.

Our assessment. Named drugs present in county formulary. Actual matching indications, continuity and modern baseline unobserved; hazard and utility transfer are priors.

20,536 high-risk adults

Randomized HPS trial. First major vascular event19.8% versus25.2%; composite includes revascularization. First-year reduction nonsignificant.

Our assessment. No mortality/additive-event credit. Attenuated short-course effect, three-year mixed-state cap and explicit null.

Insured post-MI trial participants versus heterogeneous safety-net recipients

MI FREEE randomized access trial and current partner operations. Access trial improved adherence but not its primary outcome significantly. Actual county medicine pathway verified.

Our assessment. Supports plausibility, not universal medication effect or a confirmed SIRUM treatment increment.

3. Qualitative assessment

Low-cost logistics can move otherwise unused medicines into sustained treatment, including verified BP and statin classes.

Key reservations

Central residual class expectation is weakly identified and dominates modeled health; residual-null national donor price is about$617k/10Q.
One versus three medication-months per shipped prescription materially changes value; current appeal does not specify.
No verified open marginal tranche or Bay/SF patient-residence distribution.
Gross associated and conditional net resource costs are not a complete societal account; avoided medical offsets can create a negative favorable net numerator but are uncalibrated.

Benefits not included in our estimate

Legislative/political advocacy effects
Additional mortality or recurrent events on top of first-event cardiovascular states
Retail medicine value and patient savings converted into QALYs
Duplicate Good Pill, county, manufacturer or other-partner benefits
Residual post-treatment mortality/carryover and environmental waste benefits without a quantified bridge

4. What do you get for your dollar?

Finite medication coverage and first-event catch-up

All allocation, mix, continuity, geography, utility and resource values are uncalibrated priors except the specified gift and named clinical/cost anchors. Scenarios are not probabilities.

A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.

How we calculate the estimate

Whole gift: Months=gift×delivery allocation/cash per Rx×dispensed fraction×months per Rx. N(class)=months×disjoint share/(12×funded years×concurrent drugs)×financing additionality×new treatment contrast. Qcardio=N×utility loss×discounted integral(event-free target − counterfactual). Both hazards coincide after funded coverage. Qresidual=N×mean utility gain×finite on-treatment annuity. Subtract linked and independent harms.
Central total 7.63456395046104; BP 1.5787099573144547, statin 0.2646128733159622, residual 6.012825806545966 gross QALYs; linked harm 0.12158468671534446 and alternative loss0.1.

Model inputs and assumptions

gift: 100000 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Specified gift.
delivery allocation: 0.7 (range: See bounded calculator domain and signed scenarios). 70% of ordinary gift to direct delivery pathway; remaining30% operations/expansion cost retained, no political benefits. Explicit prior / source-qualified planning anchor.
cash per shipped rx: 1 (range: See bounded calculator domain and signed scenarios). Current official $1/Rx partner-delivery appeal, not verified whole-cost marginal quote; $5 scenario. Explicit prior / source-qualified planning anchor.
months per rx: 1 (range: See bounded calculator domain and signed scenarios). Unknown quantity per shipped prescription; one month central, three-month scenario. Not one patient per Rx. Explicit prior / source-qualified planning anchor.
dispensed fraction: 0.7 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
funded years: 1 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
bp month share: 0.2 (range: See bounded calculator domain and signed scenarios). Unobserved fraction of medication-months assigned to disjoint high-risk BP patient cohorts. Explicit prior / source-qualified planning anchor.
statin month share: 0.15 (range: See bounded calculator domain and signed scenarios). Unobserved fraction of medication-months assigned to disjoint high-risk statin patient cohorts, excluding BP-attributed patients. Explicit prior / source-qualified planning anchor.
bp drugs per person: 1.5 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
statin drugs per person: 1 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
financing additionality: 0.5 (range: See bounded calculator domain and signed scenarios). Counterfactual replacement by public supply, other donors and existing stocks. Explicit prior / source-qualified planning anchor.
treatment contrast: 0.5 (range: See bounded calculator domain and signed scenarios). Meaningfully new sustained-treatment cohort fraction versus prior coverage/alternative pharmacies; not an ITT adherence correction. Explicit prior / source-qualified planning anchor.
bp transfer: 0.8 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
statin transfer: 0.35 (range: See bounded calculator domain and signed scenarios). 0.35 attenuation of HPS trial relative reduction; first-year trial benefit nonsignificant. Explicit zero scenario. Explicit prior / source-qualified planning anchor.
hazard scale: 1 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
horizon: 10 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
mortality: 0.05 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
discount: 0.03 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
delay: 0.25 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
bp utility loss: 0.4 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
statin utility loss: 0.18 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
other harm per filled rx: 0.00001 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
independent harm q: 0 (range: See bounded calculator domain and signed scenarios). Gift-date PV independent loss; retained when target effect fails. Explicit prior / source-qualified planning anchor.
displaced alternative q: 0.1 (range: See bounded calculator domain and signed scenarios). Gift-date PV opportunity health loss; retained when target effect fails. Explicit prior / source-qualified planning anchor.
us share: 1 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
bay share: 0.03 (range: See bounded calculator domain and signed scenarios). 3% Bay-resident health prior, not inferred from Palo Alto address or Santa Clara cumulative output. Explicit prior / source-qualified planning anchor.
sf share: 0 (range: See bounded calculator domain and signed scenarios). Zero central priced SF share due unverified residence throughput; not proof no SF access exists. Explicit prior / source-qualified planning anchor.
external pharmacy fraction: 0.5 (range: See bounded calculator domain and signed scenarios). Only external partner share; own disregarded Good Pill entities already inside recipient cost. Explicit prior / source-qualified planning anchor.
external dispense cost: 25 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
other external per rx: 2 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
drug opportunity per rx: 0.25 (range: See bounded calculator domain and signed scenarios). Real alternative value prior, not retail/FMV medicine price; otherwise destroyed stock may have little opportunity cost. Explicit prior / source-qualified planning anchor.
outside incremental fraction: 0.5 (range: See bounded calculator domain and signed scenarios). Independent real-resource incrementality assumption; nominal external spending is not all newly caused. Explicit prior / source-qualified planning anchor.
public resource fraction: 0.7 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
bp event cost: 25000 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
statin event cost: 15000 (range: See bounded calculator domain and signed scenarios). Definition and finite/counterfactual scope in accompanying review; not an observed SIRUM causal estimate. Explicit prior / source-qualified planning anchor.
residual utility gain: 0.019 (range: See bounded calculator domain and signed scenarios). Weighted class-mix prior0.019, not trial extraction. Averaged over initiation delays, acute-course duration, nonresponse and alternative resolution. On-treatment only; negative allowed. Explicit prior / source-qualified planning anchor.
residual drugs per person: 2 (range: See bounded calculator domain and signed scenarios). Two concurrent medicines per residual patient average; no duplicate patient benefit. Explicit prior / source-qualified planning anchor.
statin state horizon: 3 (range: See bounded calculator domain and signed scenarios). Three-year absolute follow-up cap for heterogeneous vascular first-event utility and medical costs, not persistent disability for every revascularization. Explicit prior / source-qualified planning anchor.

Entire $100,000 gift in every geography; nonpositive health is unpriced

central: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; bay: Q=0.22903691851383118; donor/gross/net per10=$4,366,108/$35,922,156/$19,124,972; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
favorable_joint: Total 101.57052556 QALYs; donor $9,845 per10. total: Q=101.57052555750553; donor/gross/net per10=$9,845/$127,473/$-2,802; us: Q=101.57052555750553; donor/gross/net per10=$9,845/$127,473/$-2,802; bay: Q=10.157052555750553; donor/gross/net per10=$98,454/$1,274,730/$-28,022; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
adverse_joint: Total -0.80985293 QALYs; donor unpriced per10. total: Q=-0.8098529254433069; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=-0.8098529254433069; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=-0.024295587763299206; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
no_additional_funding: Total -0.10000000 QALYs; donor unpriced per10. total: Q=-0.1; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=-0.1; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=-0.003; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
no_treatment_contrast: Total -0.10000000 QALYs; donor unpriced per10. total: Q=-0.1; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=-0.1; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=-0.003; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
cardiovascular_effect_null: Total 5.79124112 QALYs; donor $172,675 per10. total: Q=5.791241119830622; donor/gross/net per10=$172,675/$1,420,680/$796,677; us: Q=5.791241119830622; donor/gross/net per10=$172,675/$1,420,680/$796,677; bay: Q=0.17373723359491866; donor/gross/net per10=$5,755,819/$47,355,998/$26,555,908; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
statin_first_year_null: Total 7.36995108 QALYs; donor $135,686 per10. total: Q=7.3699510771450765; donor/gross/net per10=$135,686/$1,116,357/$606,739; us: Q=7.3699510771450765; donor/gross/net per10=$135,686/$1,116,357/$606,739; bay: Q=0.22109853231435228; donor/gross/net per10=$4,522,870/$37,211,916/$20,224,623; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
higher_full_cash_cost: Total 1.44691279 QALYs; donor $691,127 per10. total: Q=1.4469127900922079; donor/gross/net per10=$691,127/$1,690,150/$1,158,373; us: Q=1.4469127900922079; donor/gross/net per10=$691,127/$1,690,150/$1,158,373; bay: Q=0.043407383702766235; donor/gross/net per10=$23,037,555/$56,338,341/$38,612,439; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
three_month_fills: Total 23.34686122 QALYs; donor $42,832 per10. total: Q=23.346861224813807; donor/gross/net per10=$42,832/$352,403/$167,623; us: Q=23.346861224813807; donor/gross/net per10=$42,832/$352,403/$167,623; bay: Q=0.7004058367444141; donor/gross/net per10=$1,427,744/$11,746,761/$5,587,438; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
three_year_continuity: Total 6.84376385 QALYs; donor $146,118 per10. total: Q=6.843763847853477; donor/gross/net per10=$146,118/$1,202,189/$642,705; us: Q=6.843763847853477; donor/gross/net per10=$146,118/$1,202,189/$642,705; bay: Q=0.20531291543560432; donor/gross/net per10=$4,870,614/$40,072,978/$21,423,514; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
short_horizon: Total 5.97726727 QALYs; donor $167,301 per10. total: Q=5.977267265325848; donor/gross/net per10=$167,301/$1,376,465/$728,581; us: Q=5.977267265325848; donor/gross/net per10=$167,301/$1,376,465/$728,581; bay: Q=0.17931801795977542; donor/gross/net per10=$5,576,684/$45,882,171/$24,286,038; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
low_bay: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; bay: Q=0.0381728197523052; donor/gross/net per10=$26,196,650/$215,532,938/$114,749,834; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
no_local: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; bay: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
conditional_sf_reach: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$573,749; bay: Q=0.22903691851383118; donor/gross/net per10=$4,366,108/$35,922,156/$19,124,972; sf: Q=0.01526912790092208; donor/gross/net per10=$65,491,625/$538,832,345/$286,874,584
no_external_resources: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$130,983/$130,983; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$130,983/$130,983; bay: Q=0.22903691851383118; donor/gross/net per10=$4,366,108/$4,366,108/$4,366,108; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
full_external_increment: Total 7.63456395 QALYs; donor $130,983 per10. total: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$1,047,090; us: Q=7.63456395046104; donor/gross/net per10=$130,983/$1,077,665/$1,047,090; bay: Q=0.22903691851383118; donor/gross/net per10=$4,366,108/$35,922,156/$34,902,996; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
independent_harm: Total -2.36543605 QALYs; donor unpriced per10. total: Q=-2.365436049538961; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=-2.365436049538961; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=-0.07096308148616882; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
zero_gift: Total 0.00000000 QALYs; donor unpriced per10. total: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
residual_health_null: Total 1.62173814 QALYs; donor $616,622 per10. total: Q=1.6217381439150724; donor/gross/net per10=$616,622/$5,073,260/$2,701,006; us: Q=1.6217381439150724; donor/gross/net per10=$616,622/$5,073,260/$2,701,006; bay: Q=0.04865214431745217; donor/gross/net per10=$20,554,079/$169,108,682/$90,033,539; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
residual_favorable: Total 17.44496395 QALYs; donor $57,323 per10. total: Q=17.444963950614984; donor/gross/net per10=$57,323/$471,626/$251,094; us: Q=17.444963950614984; donor/gross/net per10=$57,323/$471,626/$251,094; bay: Q=0.5233489185184494; donor/gross/net per10=$1,910,771/$15,720,869/$8,369,798; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced
residual_harm: Total -1.54290702 QALYs; donor unpriced per10. total: Q=-1.54290701742491; donor/gross/net per10=unpriced/unpriced/unpriced; us: Q=-1.54290701742491; donor/gross/net per10=unpriced/unpriced/unpriced; bay: Q=-0.0462872105227473; donor/gross/net per10=unpriced/unpriced/unpriced; sf: Q=0; donor/gross/net per10=unpriced/unpriced/unpriced

5. Funding and previous grants

No verified additional whole-gift package or geographically allocated completed courses. Central result does not establish sub-$100,000/10-QALY value.

Ordinary unrestricted gift, not a verified additional course offer. All donor dollars remain in every regional numerator. Current $1 partner-delivery appeal does not establish months dispensed, high-risk uptake or marginal capacity. Public external pharmacy resources and donor-drug opportunity costs are counted separately; internal disregarded pharmacies are not double-counted. Gross resources exclude avoided medical offsets; conditional net includes them. No fiscal or health benefit from political advocacy is modeled.

This review does not establish a verified marginal funding offer or a complete history of grants.

Donate

Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.

6. Sources

Ordinary monetary support and delivery price anchor. SIRUM. Official fundraising page; $1/Rx claim not marginal quote. Published: Undated; current September 2026; retrieved: September 8, 2026.
Impact, including 2024 results. SIRUM. Official self-report; partner reach not causal outcomes. Published: 2024 section; otherwise undated; retrieved: September 8, 2026.
FY2024 Form 990. SIRUM / IRS. Primary tax e-file reproduced by ProPublica; fetched via public HTTP. Published: Signed November 17, 2025; FY2024; retrieved: September 8, 2026.
FY2024 noncash contributions. SIRUM / IRS. Primary Schedule M; FMV not real opportunity cost. Published: FY2024; retrieved: September 8, 2026.
FY2024 disregarded entities. SIRUM / IRS. Primary Schedule R; internal entity scope. Published: FY2024; retrieved: September 8, 2026.
Surplus medication intermediaries. California Board of Pharmacy. Primary regulator license listing. Published: Undated current listing; retrieved: September 8, 2026.
Current medication access and formulary. County of Santa Clara. Official current service and medication-class evidence; not stock guarantee. Published: Undated; current September 2026; retrieved: September 8, 2026.
County pharmacy partnership with SIRUM. County of Santa Clara. Official county operating account. Published: February 20, 2024; retrieved: September 8, 2026.
Unused prescriptions and pharmacy operating costs. County of Santa Clara. County-hosted reported account; historical approximate cost, not current quote. Published: December 8, 2023; retrieved: September 8, 2026.
Prevention of stroke by antihypertensive treatment. SHEP Cooperative Research Group / JAMA. Primary randomized trial abstract. Published: June 26, 1991; retrieved: September 8, 2026.
Simvastatin in 20,536 high-risk individuals. Heart Protection Study Collaborative Group / Lancet. Primary randomized trial abstract; first-year effect nonsignificant. Published: July 6, 2002; retrieved: September 8, 2026.
Full coverage for preventive medicines after MI. Choudhry et al. / NEJM. Primary randomized access trial; primary outcome nonsignificant. Published: December 1, 2011; retrieved: September 8, 2026.

Annual expenses: years and sources

Average annual expenses (three consecutive fiscal years): Not available. Organization size is separate from the modeled cost-effectiveness of a donation.

SIRUM

Three years of organization-level expenses have not yet been verified for this report. No other organization or fiscal sponsor budget has been substituted.